Special Issue

Advances in Glycoconjugate Vaccines and Nanovaccines

Message from the Guest Editors

Glycoconjugate vaccines, obtained by linking carbohydrates to protein carriers, have had a critical role in fighting infectious diseases and, despite the new mRNA-based technologies, still are a valuable strategy to develop anti-infection and anti-cancer vaccines, from preclinical to clinical stages. Indeed, they are particularly effective in targeting carbohydrates, which are one of the most important classes of surface antigens, and which can also be used as adjuvants to promote immunostimulant effects as well as for promoting antigen or nucleic acid delivery for vaccine development. This Special Issue will focus on recent advancements in the design, development, and characterization of glycosylated proteins and nanoparticles as potential vaccines. The Special Issue is open to original research articles and reviews on antigenic/immunogenic oligosaccharides or new glycoderivatives, as well as pre-clinical and clinical studies on anti-infection or anticancer glyco-(nano)vaccines. Investigations on analytical approaches to support the design and production of glycoconjugates will also be considered.

Guest Editors

Prof. Dr. Marco Terreni

Department of Drug Sciences, School of Pharmacy, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy

Dr. Sara Tengattini

Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy

Deadline for manuscript submissions

closed (31 August 2025)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/190673

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

